Hypoxia is associated with resistance to radiotherapy and chemotherapy in malignant gliomas, and it can be imaged by positron emission tomography with18F-fluoromisonidazole (18F-FMISO). Previous results for patients with brain cancer imaged with18F-FMISO at a single center before conventional chemoradiotherapy showed that tumor uptake via T/Bmax (tissue SUVmax/blood SUV) and hypoxic volume (HV) was associated with poor survival. However, in a multicenter clinical trial (ACRIN 6684), traditional uptake parameters were not found to be prognostically significant, but tumor SUVpeak did predict survival at 1 year. The present analysis considered both study cohorts to reconcile key differences and examine the potential utility of adding radiomic features as prognostic variables for outcome prediction on the combined cohort of 72 patients with brain cancer (30 University of Washington and 42 ACRIN 6684). We used both18F-FMISO intensity metrics (T/Bmax, HV, SUV, SUVmax, SUVpeak) and assessed radiomic measures that determined first-order (histogram), second-order, and higher-order radiomic features of18F-FMISO uptake distributions. A multivariate model was developed that included age, HV, and the intensity of18F-FMISO uptake. HV and SUVpeak were both independent predictors of outcome for the combined data set (P <.001) and were also found significant in multivariate prognostic models (P <.002 and P <.001, respectively). Further model selection that included radiomic features showed the additional prognostic value for overall survival of specific higher order texture features, leading to an increase in relative risk prediction performance by a further 5%, when added to the multivariate clinical model..
- ACRIN 6684
- Brain cancer
- PET imaging
ASJC Scopus subject areas
- Radiology Nuclear Medicine and imaging